Project
PsoA: A phase III, randomized, double-blind, placebo-controlled multicenter
Completed · 2014 until 2018
Müller Rüdiger, Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2014
End Date
2018
Financing
Industry
Keywords
Psoriasis Arthritis, Secukinumab
Brief description/objective
Study to demonstrate the efficacy at 24 weeks and to assess the long
term efficacy, safety and tolerability of secukinumab in Active Psoriatic
Arthritis